Literature DB >> 11803235

Increased [(3)H]tiagabine binding to GAT-1 in the cingulate cortex in schizophrenia.

Ingrid Sundman-Eriksson1, Kaj Blennow, Pia Davidsson, Anna-Karin Dandenell, Jan Marcusson.   

Abstract

Postmortem samples from individuals with schizophrenia (n = 13) and control subjects (n = 10) were investigated for binding of [(3)H]tiagabine to GABA transporter-1 GAT-1. The binding was analyzed in the cingulate cortex and the caudate nucleus. There were no differences in binding affinity between the groups in any of the investigated areas. The maximum number of binding sites (B(max)) was elevated in the schizophrenic cingulate cortex compared to controls (1,264 +/- 96 vs. 860 +/- 123 fmol/mg of protein). The B(max) in the caudate nucleus for schizophrenics (426 +/- 40 fmol/mg of protein) was the same as for controls (495 +/- 69 fmol/mg of protein). The increase in GAT-1 in schizophrenia could be explained by a modulatory upregulation in the cingulate cortex. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11803235     DOI: 10.1159/000048666

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  3 in total

Review 1.  Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6.

Authors:  Nian-Hang Chen; Maarten E A Reith; Michael W Quick
Journal:  Pflugers Arch       Date:  2003-04-29       Impact factor: 3.657

Review 2.  SLC transporters as therapeutic targets: emerging opportunities.

Authors:  Lawrence Lin; Sook Wah Yee; Richard B Kim; Kathleen M Giacomini
Journal:  Nat Rev Drug Discov       Date:  2015-06-26       Impact factor: 84.694

3.  Development of Positron Emission Tomography Radiotracers for the GABA Transporter 1.

Authors:  Alexandra R Sowa; Allen F Brooks; Xia Shao; Bradford D Henderson; Philip Sherman; Janna Arteaga; Jenelle Stauff; Adam C Lee; Robert A Koeppe; Peter J H Scott; Michael R Kilbourn
Journal:  ACS Chem Neurosci       Date:  2018-05-24       Impact factor: 4.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.